India’s Alembic Pharmaceuticals says its US front-end business has passed the “milestone” of $250m in annual sales for its financial year ended 31 March 2020 after the business grew by more than half – 53% – to INR19.76bn ($263m), boosted by fourth-quarter growth of 84% to INR5.77bn.
Alembic credited its “well-established US front-end that has a strong customer base” that helped expand the company’s ability “to deliver...







